Journal profile · Pharmacology & Pharmacy
Expert Opinion on Pharmacotherapy
ISSN 1465-6566 · eISSN 1744-7666 · Taylor and Francis Ltd. · ENGLAND · Monthly · Founded 1999
Expert Opinion on Pharmacotherapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.65; subscription journal; median 63 days to acceptance (101 articles, last 24 months); community-reported acceptance: easy; 168 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Opinion on Pharmacotherapy is published by Taylor and Francis Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Treatment and Management, Blood Pressure and Hypertension Studies and Asthma and respiratory diseases, together about 19% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Treatment and ManagementMedicine9%
- Blood Pressure and Hypertension StudiesMedicine5.1%
- Asthma and respiratory diseasesMedicine4.9%
- Lipoproteins and Cardiovascular HealthMedicine4.9%
- Schizophrenia research and treatmentMedicine4.8%
- Diabetes Management and ResearchMedicine4.5%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine4.2%
- Bipolar Disorder and TreatmentMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.65LetPub ·
- CiteScore 2026-06
- 4.8LetPub ·
- SJR 2026-06
- 0.77LetPub ·
- SNIP 2026-06
- 0.75LetPub ·
- h-index
- 69LetPub ·
- h-index
- 119OpenAlex ·
- i10-index
- 3,752OpenAlex ·
- 2-year mean citedness
- 3.75OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 4.26%LetPub ·
Volume
- Articles per year
- 140LetPub ·
Articles by year OpenAlex count · 6,580 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 155 | 45 | 38 |
| 2025 | 168 | 52 | 457 |
| 2024 | 224 | 59 | 1,554 |
| 2023 | 175 | 58 | 1,605 |
| 2022 | 194 | 55 | 1,730 |
| 2021 | 211 | 65 | 2,682 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
63 daysMedian, submission to acceptance · P25–P75 50 days – 90 days
- Acceptance to online
- median 7 days (101 articles)
- Submission to online
- median 72 days
- Sample
- 101 articles with submission and acceptance dates (389 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 1999
- ISSN
- 1465-6566
- Electronic ISSN
- 1744-7666
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Expert Opinion on Pharmacotherapy
What CAS zone is Expert Opinion on Pharmacotherapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Opinion on Pharmacotherapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Opinion on Pharmacotherapy?
The latest impact factor listed by LetPub is 3.65; CiteScore 4.8, h-index 119.
How long does peer review take at Expert Opinion on Pharmacotherapy?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 63 days (interquartile range 50–90 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Expert Opinion on Pharmacotherapy?
According to LetPub and DOAJ records, Expert Opinion on Pharmacotherapy is indexed in SCIE and Scopus.
Is Expert Opinion on Pharmacotherapy open access, and what is the APC?
Expert Opinion on Pharmacotherapy is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .